Pharmaceuticals.jpg

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

2753-45-9

Mebeverine HCl

2753-45-9
33045-52-2

Methyl 2-methoxy-5-sulfamoylbenzoate

33045-52-2
3562-63-8

Megestrol

3562-63-8
59467-70-8

Midazolam

59467-70-8
2921-57-5

Methylprednisolone Hemisuccinate

2921-57-5
54238-51-6

Mapenterol HCl

54238-51-6
162462-69-3

Medroxyprogesterone D3

162462-69-3
NA

Melengestrol Acetate D3

NA
119-36-8

Methyl Salicylate

119-36-8
71-58-9

Medroxyprogesterone 17-acetate

71-58-9
59122-46-2

Misoprostol

59122-46-2
51930-97-3

3-MCPD-1,2-dipalmitoyl Ester

51930-97-3
71125-39-8

Meloxicam sodium salt

71125-39-8
73573-88-3

Mevastatin

73573-88-3
25717-80-0

Molsidomine

25717-80-0
26155-31-7

Morantel Tartrate hydrate

26155-31-7
3963-95-9

Metacycline HCl

3963-95-9
6385-02-0

Meclofenamate Sodium

6385-02-0
351329-88-9

Memantine Related Compound E

351329-88-9
03/03/2375

Methylprednisolone sodium succinate

03/03/2375